AR and prostate cancer: In a minority of patients, therapeutic resistance to androgen receptor deprivation therapy is associated with the emergence of a peculiar histologic subtype termed small cell neuroendocrine (t-SCNC) prostate cancer: a highly aggressive prostate cancer subtype observed in <1% of de novo prostate cancers [91].